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Background: Pulmonary alveolar proteinosis (PAP) is a rare syndrome characterized by the
intra-alveolar accumulation of surfactant lipids and proteins. The aim of the study is to
describe the epidemiologic, clinical, physiologic, and laboratory features of PAP in a large
single-center cohort of patients with PAP.
Study population: Over 30 years, 70 patients with PAP were managed at our institution, 64
with primary and 6 with secondary PAP.
Results: The mean age at diagnosis was 43 years with a male to female ratio of 1.3. BAL was the
most commonly applied diagnostic method, performed in 83% of cases. A history of smoking was
seen in 79%, andof dust exposure in 54%,most commonly to aluminum, silica and sawdust.GM-CSF
autoantibody correlated with clinical outcome and KL-6 with diffusing capacity. The number of
whole lung lavages (WLL) necessary to reach remission was higher in current smokers.
Conclusions: This study shows that the use of BAL for the diagnosis of PAP can reduce the need of
histological confirmation. A history of dust or fume inhalation is strongly associatedwith PAP, also
with the autoimmune form. Smoking seems to influence the response to treatment, increasing the
number of WLL necessary to reach remission.
ª 2011 Elsevier Ltd. All rights reserved.) 201 433 4021; fax: þ49 (0) 201 433 4029.
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List of abbreviations
BAL Bronchoalveolar lavage
DLCO Diffusing capacity of the lung for carbon
monoxide
DSS Disease severity score
ELISA Enzyme-linked immunosorbent assay
FEV1 Forced expiratory volume in 1 s
GM-CSF Granulocyte macrophage colony
stimulating factor
HRCT High resolution computed tomography
KL-6 Krebs von den Lungen 6
PAP Pulmonary alveolar proteinosis
TBB Transbronchial biopsy
TLC Total lung capacity
VC Vital capacity
WLL Whole lung lavage
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Pulmonary alveolar proteinosis (PAP), first described in
1958,1 is a rare syndrome characterized by the intra-
alveolar accumulation of surfactant lipids and proteins.
There are three distinct clinical forms: hereditary, primary
(autoimmune or idiopathic), and secondary.2e5 Primary
autoimmune PAP is the most frequent and is associated
with the presence of GM-CSF autoantibodies.6,7 Secondary
PAP occurs as a consequence of hematological disorders,
inhalation injuries or infections.8 Hereditary PAP is caused
by mutations in the GM-CSF receptor gene.9
Epidemiology and natural history of primary PAP have
been assessed in large cohorts in comprehensive
reviews2,10,11 and in a large national cross-sectional study,12
which provided demographic and outcome data, clinical
features and laboratory profiles of the patients. Some
consistent differences exist between the published cohorts
with regards to the diagnostic methods, the classification of
the patients and the role of GM-CSF autoantibody in
assessing the activity of disease.2,10,12
The aim of the current study was to describe the
epidemiologic, clinical, physiologic, and laboratory
features of PAP in a large single-center cohort of patients
with PAP. Some of the results of this study have been
previously reported in the form of an abstract.13
Materials and methods
Study population
This study was conducted at the Ruhrlandklinik, a referral
center for the diagnosis and therapy of PAP in Germany.
The study includes a retrospective cross-sectional analysis
and a prospective data collection starting in 2007. Between
1978 and 2010, all subjects diagnosed with PAP at our
institution and those that were referred to our center were
recruited. The study population comprised both prevalent
and incident cases. All patient-related historical, physical
examination and other data were collected at time ofdiagnosis, when possible. All physicians and patients of the
retrospective part of this study received a recruitment
letter and follow phone calls to ensure participation. The
study was approved by the local IRB (06-3170). Informed
consent was obtained from the patients.
70 patients with PAP were enrolled in the study (35
retrospectively and 35 prospectively); 64 had primary, and
6 secondary PAP. Demographics of the patients are shown in
Table 1.
The diagnosis of PAP was based on diagnostic BAL find-
ings,14 characteristic HRCT,15e18 and/or histopathologic
findings on biopsy.1,2,19Disease severity score and stratification of the
patients
Patients were assigned a PAP disease severity score (DSS)
based on the presence of symptoms (dyspnea or cough) and
grade of reduction in PaO2 as previously described12,20
(Table 1).
Patients were stratified as improved, stable or worsened
according to the disease course during the observational
period. Patients who were improved or were stable and did
not receive WLL within 12 months prior to the last evalu-
ation were considered to be in remission.Pulmonary function tests
Measurements included vital capacity, FEV1, TLC, DLCO
and DLCO/VA and arterial blood gas analysis.Serum sampling
Serum samples were stored at 20 or 80 C until analysis.
GM-CSF autoantibody concentration was measured by ELISA
as previously reported.21,22 As a modification, a human IgG1
antibody specifically detecting human GM-CSF, BI01049904
(Boehringer Ingelheim, Germany) was used to quantify GM-
CSF antibody levels. The detection limit of this assay is
0.2 mg/mL. GM-CSF values <10 mg/mL are to be considered
as normal.23 Serum KL-6 was measured by ELISA (Eisai Co.
Ltd., Tokyo, Japan) as described previously.24 The normal
range in Europeans is <500 U/ml.25 Serum CEA and LDH
were routinely measured (normal value for CEA < 2.5 ng/ml
and for LDH < 225 IU/l).Statistics
All continuous variables were evaluated for a normal
distribution with KolmogoroveSmirnov test. Parametric
data are presented as mean  SE and nonparametric data
are presented as median and interquartile range (IQR).
Categorical variables are presented as either a percentage
of the total or numerically, as appropriate. For comparisons
we used Student’s t-test and Wilcoxon test for continuous
variables, Chi-squared or Fischer’s exact test for categor-
ical variables. Spearman’s or Pearson’s correlation coeffi-
cient was obtained for correlations. P values of less than
0.05 were considered statistically significant.
Table 1 Demographics and disease features at diagnosis.
Characteristics n % mean  SD (range)
Gender M/F 39/31
Age (years) 43  13
PAP Type
Primary 64 91
Secondary 6 9
Smoking habits
Never 15 21
Previous 21 30
Current 34 49
Previous dust/fume exposure 38 54
Radiographic PAP features
Characteristic 68 97
Non characteristic 2 3
CT (35 HRCT/6 CT) PAP features (n Z 41)
Characteristic 39 95
Non characteristic 2 5
Pulmonary function
FEV1 (% pred.) 65 71  15
FVC (% pred.) 65 70  15
TLC (% pred.) 62 76  15
DLCO (% pred.) 25 47  18
FEV1/FVC < 0.7 (n Z 65) 6 9
TLC <80% pred. (n Z 62) 37 60
DLCO< 80% pred. (n Z 25) 23 92
Blood gas analysis
PaO2 mmHg 70 69  14
PaCO2 mmHg 68 35  5
AaDO2 mmHg 52 36  15
DSS gradea 70
DSS 1 3 4
DSS 2 29 41
DSS 3 19 28
DSS 4 10 14
DSS 5 9 13
Serology
GM-CSF Ab mg/mL 42 64  25 (39e122)
LDH U/L 65 353  170 (173e894)
KL-6 U/mL 15 3350  3026 (700e10,487)
CEA ng/mL 32 8.5  7(1e27)
a DSS 1Z no symptoms and PaO2  70 mmHg; DSS 2Z symptomatic and PaO2  70 mmHg; DSS 3Z 60 mmHg  PaO2 < 70 mmHg; DSS
4 Z 50 mmHg  PaO2 < 60 mmHg; DSS 5 Z PaO2 < 50 mmHg.
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64 of 70 patients (91%) had primary PAP (Table 1). Among
the patients with secondary PAP, 3 had chronic myeloid
leukemia, 2 were post-infectious (both P. jirovecii), and 1
had a nephrotic syndrome.
The median age at diagnosis was 43 years. A male
predominance (38 M vs 26 F) was seen in patients with
primary PAP, in contrast to a female predominance in
secondary PAP (5 F vs 1 M). Detailed demographics are
illustrated in the Table 1.Diagnostic methods
In the patients directly diagnosed at our center (n Z 36),
bronchoscopic evaluation with BAL was the most frequently
applied diagnostic method. BAL was used in 83% of cases. It
was used alone in 49% of cases and combined with trans-
bronchial biopsy in 31%. Surgical biopsy was performed in
20% of cases. In the patients referred to our center after
diagnosis (nZ 34), BAL was used alone in 29% of cases, and
surgical biopsy in 41% of cases.
All 35 patients who underwent HRCT showed charac-
teristic features of PAP. Pulmonary function tests revealed
the presence of restriction in 60% of cases. Arterial blood
gas analysis showed mild hypoxemia (PaO2 Z 69 mmHg,
mean) with increased AaDO2 (36 mmHg, mean) at rest. The
diffusion capacity was reduced in 92% of patients.
Pulmonary alveolar proteinosis: New insights 1911Characteristic BAL findings (acellular globules, foamy
macrophages, and PAS positive cell debris) were seen in all
patients. BAL cell differential counts at time of diagnosis
revealed the presence of lymphocytosis, defined as
lymphocyte percentage > 13%, in 30 cases (63%). The mean
percentage of lymphocytes was 38  18% (range 16e87%).
Neutrophilia > 3% was detected in 10 patients (21%), with
a mean percentage of 25  28%.
Exposure to dust and/or fumes
Dust/fume exposure was evident from the history (occupa-
tion or specific risk factors) in 38 patients (54%). The type of
inhaled agents is reported in Table 2. In 36 patients (95%) the
exposure was occupational, for at least 5 h a day for at least
5 years. 21 patients did not use airway protection before the
first evaluation in our center. Dust inhalation was mostly due
to handling of silica, aluminum, and sawdust (Table 2). 15
patients were exposed to more than one substance simul-
taneously. We registered a male predominance among the
exposed patients (92% male, p < 0.001).
Smoking habits
55 of 70 patients (79%) were current or exsmokers (67%
males, 33% females, pZ 0.02) (Table 1). All active smokers
at time of diagnosis reported a heavy consumption of more
than 20 cigarettes daily.
Symptoms
Exertional dyspnea was the most commonly reported
symptom (94%), followed by cough (66%), fatigue (49%) and
weight loss (43%).
Comorbidity
Most patients (70%) had comorbidity: depression and
hypertension were the most common (Table 3). During
the observational period pneumonia occurred in 8
patients (11%) including one case of P. jirovecii, one of E.
Coli, one of Legionella and one of Haemophilus
influenzae.Table 2 Dust or fume exposure (n Z 38).
n %
Aluminum dust 7 18
Bakery flour dust 3 8
Cement dust 2 5
Chlorine 1 3
Cleaning products 3 8
Gasoline fumes 3 8
Paint 5 13
Petroleum 1 3
Saw dust 5 13
Silica (glass grinding) 8 21
Synthetic plastic fumes 4 11
Titanium 3 8
Varnish 2 5GM-CSF autoantibody levels
All subjects affected by secondary PAP were negative for
GM-CSF autoantibodies.
The mean GM-CSF antibody concentration in our auto-
immune cohort was 64  25 mg/ml and was higher in women
than in men (81  30 vs 52  12 mg/ml, respectively,
p Z 0.023).
In 10 patients GM-CSF autoantibodies were also
measured at time of remission. Serum levels were signifi-
cantly higher at diagnosis before any WLL treatment than at
remission (72  28 vs 52  22 mg/ml respectively,
pZ 0.002). The difference in serum levels between women
and men was also confirmed at time of remission (63  21 vs
35  6 mg/ml respectively, p Z 0.006).
GM-CSF autoantibody levels showed a weak inverse
correlation with age (r Z 0.44, p Z 0.04). They also
correlated with the duration of disease (r Z 0.45,
p Z 0.04).Other biomarkers
In Table 1 the mean serum levels of KL-6, LDH and CEA are
shown. KL-6 correlated with AaDO2 and inversely with PaO2
and DLCO (Fig. 1). CEA correlated with AaDO2 (r Z 0.438,
p Z 0.009) and inversely with PaO2 (r Z 0.471,
p Z 0.031). LDH correlated inversely with DLCO
(r Z 0.47, p Z 0.02).Disease severity score
The distribution of the patients according to DSS is shown in
Table 1. DSS correlated with age (r Z 0.421, p < 0.001)
and inversely with DLCO% (r Z 0.523, p Z 0.007). In
regard to biomarkers, DSS correlated only with CEA
(rZ 0.506, pZ 0.003) but not with GM-CSF antibody serum
levels.Analysis of disease course, remission and treatment
The mean duration of disease, defined as time from diag-
nosis to remission, death or last follow-up visit, was 3.1
years. 12 patients died during the follow-up, 8 of them from
progression of PAP and 4 of them from other causes: sudden
death, liver cirrhosis, diabetes and myocardial infarction.
There was a marked difference in the incidence of PAP
related death between primary PAP (5/64 Z 8%) and
secondary PAP (3/6 Z 50%).
43 patients reached a remission, two occurred sponta-
neously (Table 4). FVC, TLC, PaO2, AaDO2 and DLCO
improved significantly in patients with remission (Fig. 2).
Of 63 lavaged patients, 40 received at least one WLL
(range 1e16) and reached remission. 10 patients are
currently receiving ongoing treatment with WLL. Active
smokers needed a higher number of WLL (Table 5). With
regard to GM-CSF treatment, only one female patient with
primary PAP and high GM-CSF autoantibody titer was
treated with inhalation of aerosolized GM-CSF for 12
months, and responded.
Table 3 Comorbidity at time of diagnosis.
Total Male Female
n Z 70 % n Z 39 % n Z 31 % p
No comorbidity 21 30 10 26 11 35 0.50a
Depression 11 16 7 18 4 13 0.80a
Hypertension 10 14 9 23 1 3 0.04a
Pneumonia 8 11 3 8 5 16 0.46a
COPD 7 10 4 23 3 4 0.15a
Obesity 6 9 5 13 1 3 0.31a
Diabetes 4 6 3 8 1 3 n.d.
Pulmonary embolism 3 4 0 0 3 10 n.d.
OSAS 3 4 1 2 2 6 n.d.
Pulmonary Hypertension 2 3 1 2 1 3 n.d.
Gastroesophageal reflux disease 2 3 2 5 0 0 n.d.
Inflammatory bowel disease 2 3 0 0 2 6 n.d.
Tuberculosis (inactive) 2 3 1 2 0 0 n.d.
n.d. Z not determined.
a Fisher’s Exact test: male vs female
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In this study we report on the demographic, clinical,
physiologic, diagnostic and serum biomarker data fromFigure 1 Correlations of serum KL-6 levels with arterial blood gas
patients, r and p are indicated in each chart.a single center cohort of 70 patients with PAP assem-
bled during 31 years. To the best of our knowledge,
this is the largest single-center cohort reported
worldwide.parameters, diffusing capacity and serum CEA. The number of
Table 4 Outcome and remission (n Z 70). Definition and criteria of remission are reported in the text.
Characteristics n Z 70 (%) Range
Loss of follow-up 9 13
Remission (stable/improved) 43 (15/28) 70 (35/65)
Spontaneous 3 7
After treatment with WLL 40 93
No Remission (requiring WLL/
dead from PAP)
18 (10/8) 30
Treatment with at least 1 WLL 63/70 90
Remission reached after WLL 21/40 52
Average number of WLL to reach
remission (mean  SD)
3.9  3 1e16
Frequency of WLL to reach
remission (per year) (mean  SD)
1.4  0.8 0.2e4
Time to remission (years, mean  SD) 3.7  3.4 1e17
Remission by gender
Male 27 63
Female 16 37
Remission by PAP type
Primary 42
Secondary 1
Remission by DSS at diagnosis
DSS 1 (n Z 3) 1/3 33
DSS 2 (n Z 28) 16/28 57
DSS 3 (n Z 17) 16/17 94
DSS 4 (n Z 9) 6/9 67
DSS 5 (n Z 7) 4/7 57
Pulmonary alveolar proteinosis: New insights 1913Our data differ in several aspects from large published
cohorts in regard to demographics, diagnostic methods and
the controversial role of GM-CSF autoantibodies as
biomarker of disease activity or extent.
First, we found a higher proportion of current smokers,
with a remarkably high rate of smoking females, in
comparison with the published cohorts. Second, we found
a higher proportion of patients with exposure to dust and
fumes including a relevant proportion of patients with
sawdust exposure. Third, we frequently diagnosed PAP by
BAL which is based on the great experience of our center in
the interpretation of BAL findings. Fourth, we found that
GM-CSF autoantibodies correlated with the outcome of
disease, and KL-6 serum levels with the diffusing capacity.
The median age at diagnosis in our cohort was 43 years,
contrasting with the older age of 51 years in the Japanese
cohort.12 This could be either due to the fact that the
Japanese cohort included only patients with autoimmune
PAP, or due to real differences in age of manifestation
between Caucasian and Asian populations.
With respect to smoking habits, the proportion of
current smokers (49%) was the highest and of never smoker
the lowest in our cohort2,10,12 (Table 6). In contrast to the
Japanese data,12 in our cohort the proportion of current
smokers was about two fold higher than reported in
Germany (27%) for the same age matched population.26
Exposure to inhaled dusts can cause secondary PAP.
Patients with these secondary forms have been considered
autoantibody-negative. However the secondary cases in the
Japanese cohort which all tested negative for the autoan-
tibody have been limited to those with hematologic orautoimmune comorbidity. In our cohort a history of dust or
fume exposure occurred in 54% of our patients with primary
PAP. In the Japanese cohort, this was seen in 26%, and the
type of dust was not specified. In our study, the patients
completed a short questionnaire referring to type,
frequency, duration and intensity of dust exposure. The
recent report by Cummings et al27 about the occurrence of
autoimmune alveolar proteinosis in indium workers
supports the hypothesis that an inhaled agent may be the
trigger for the development of autoimmune PAP. The
underlying mechanism needs further investigation.
The analysis of comorbidity showed that depression was
present in 11 patients which has not been reported before.
Pneumonia occurred in 14% of our patients which is similar
to the frequency reported by Seymour et al2 and Inoue
et al12 (13% and 6%, respectively). The comorbidities of our
PAP cohort are also frequent in the general population and
do not suggest a casual association with PAP.
In our center, BAL was the principal diagnostic tool for
the diagnosis of PAP performed in 83% of patients. This is
similar to that reported by Inoue et al12 and Xu et al10 but
very different from Seymour’s cohort with only 4% BAL
performance.2
The DSS seems to be a useful tool to assess disease
severity, as previously described by Inoue et al.12,20 We did
not find a correlation of the DSS with spirometry or with
GM-CSF autoantibody levels. DSS seems to be influenced by
age. Inoue et al already pointed out that pulmonary func-
tion tests may be of limited usefulness in assessing the
severity of PAP lung disease and that the DSS may be better
in this regard.12
Figure 2 Paired lung function data from patients with primary PAP at diagnosis and at remission. The number of evaluable
patients is indicated. The horizontal heavy line represents the mean value.
1914 F. Bonella et al.We also confirmed the previously reported difference
between men and women in serum GM-CSF antibody
levels.12 Our observation that GM-CSF autoantibody levels
did not correlate with DSS, spirometry, DLCO, PaO2, orTable 5 Analysis of the distribution of performed WLL according
at diagnosis.
PAP Type Smoking habits Dus
primary secondary never former active Yes
treated
with
WLL
No 4 3 3 2 2 2
Yes 60a 3a 12 19 32 36
number
of
WLL
4.2  4.3b 1  1b 2.4  1.9c 3.8  5.4 5. 4c 4.4
frequency
of WLL/
year
1.9  1.75 1.5  1.96 1.4  1.6 1.9  1.3 2.1  2 1.9
a p Z 0.01 (Fisher’s PLSD test).
b p Z 0.074 (Fisher’s PLSD test).
c p Z 0.009 (Student’s t-test).
d p Z 0.08 (Student’s t-test).AaDO2 is consistent with previous studies.2,12,28 In contrast
to Inoue et al12 we found that the antibody levels corre-
lated well with the duration of disease. In patients under-
going remission, we found a significant decline in theto PAP type, smoking habits, history of dust exposure and DSS
t Exposure DSS
No 1 2 3 4 5
5 1 2 1 1 2
27 2 27 18 9 7
 5 3.3  2.6 2.6  2.5 4  3.8 4.7  5.8 4.3  3.7 2  1.3
 2 1.9  1.5 0.75  1 2.1  1.9 1.6  1.2d 2.8  2.2d 1.3  1.4
Table 6 Comparison between published cohorts.
Seymour (2002) Inoue (2008) Xu (2009) Bonella (2011)
(n Z 410) (n Z 248) (n Z 241) (n Z 70)
Age at Diagnose
(mean, range)
39 (30e46) 51 (41e58) 42 (n.a) 43 (18e78)
Ratio Male/Female 2.6 2.0 2.2 1.3
Primary PAP (%) n.a 90 n.a. 91
Secondary PAP (%) n.a 10 n.a. 9
Time to diagnosis
(months)
7 (3e19) 10 (4e36) n.a. 9 (1e36)
Spontaneous
remitters (%)
6 5 n.a. 7
Smoking habits (%)
never 28 43 e 21
previous n.a. 29 e 30
current n.a. 29 e 49
Dust exposure (%) n.a 26 n.a. 54
Elevated LDH 82 n.a n.a. 80
PaO2 mmHg
(mean, range)
60 (46e70) 72 (58e85) n.a. 69 (36e96)
AaDO2 mmHg 48 (34e60) 31 (11e60) n.a. 36 (11e66)
Whole lung lavage 54% n.a. 59% 90%
Diagnostic methods
autopsy % 11 0 n.a. 0
surgical biopsy % 71 44 n.a. 34
transbronchial
biopsy %
10 12 n.a. 29
BAL % 4 70 72 76
n.a. Z not available.
Pulmonary alveolar proteinosis: New insights 1915antibody levels. GM-CSF autoantibody measurements can
provide adjunct information in the follow-up of the
patients.
We can only speculate as to why WLL, bringing patients
into remission, should affect serum GM-CSF autoantibody
levels. Pulmonary compartmentalization of GM-CSF auto-
antibodies seems to be an important factor in determining
disease severity.5,12 Lin et al. reported that BAL fluid levels
of GM-CSF autoantibodies correlate with severity markers
of PAP, like serum LDH, PaO2, AaDO2 and DLCO.29 They also
showed that patients who required subsequent WLL had
significantly higher baseline values of GM-CSF autoanti-
bodies in BAL fluid.29 Therefore we can postulate that WLL
allows to remove GM-CSF autoantibodies from the lung and
reduce the consequent spillover into the circulation.
KL-6 has been routinely used in Japan as biomarker of
interstitial lung disease in general. Takahashi et al24
demonstrated that serum and BAL-fluid KL-6 levels were
extremely high in 4 patients with PAP. Lin et al30 showed in
15 patients with primary PAP that KL-6 at diagnosis may
serve as disease severity marker and as aid in determining
the need for subsequent WLL. Our study confirmed the
correlation of KL-6 with the magnitude of functional
impairment.
WLL is still the gold standard in the treatment of
PAP.2,4,10,12 We performed at least one WLL in 90% of the
patients, which is a much higher rate than in the cohort of
Xu et al10 and Seymour et al (54%).2 An interesting finding
from our series is that active smokers require on average 5WLL to achieve remission, which is twice as much as the
number needed in nonsmokers (2.4).
There are several limitations of this study. First, there
were 13% of patients who were lost during follow-up.
Second, we did not succeed to collect consistent follow-
up data at predefined regular intervals. Third, the serial
GM-CSF autoantibody measurements have been impaired by
the lack of concomitant measurement of neutralizing
antibodies.Conclusions
Our study supports the concept that the use of BAL for the
diagnosis can reduce the need of histologic confirmation.
The inhalation of dust or fumes is strongly associated with
PAP, also with the primary autoimmune form. GM-CSF
autoantibody levels need to be further investigated for
their relationship with the outcome of the disease. Smoking
seems to influence the response to treatment, increasing
the number of WLL necessary to reach remission.Funding sources
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